Advances in research on radioiodine therapy of carcinoma mediated by gene transfer technology.
- Author:
Da MU
1
;
Anren KUANG
Author Information
1. Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Gene Expression Regulation, Neoplastic;
Gene Transfer Techniques;
Genetic Therapy;
methods;
Humans;
Iodine Radioisotopes;
therapeutic use;
Neoplasms;
genetics;
radiotherapy;
Symporters;
genetics;
metabolism
- From:
Journal of Biomedical Engineering
2010;27(5):1187-1192
- CountryChina
- Language:Chinese
-
Abstract:
Radioiodine therapy of carcinoma could be mediated by transferring the genes which participate in the process of iodine metabolism in thyroid. The correlative genes are sodium/iodine symporter gene, thyroid peroxidase gene and the specific thyroid transcription factors, and others. The objective gene can specifically express in carcinoma by inserting the tissue-specific promoter/enhancer upstream of them, so radioiodine could be used to treat varied carcinomas. The radioiodine uptake in carcinoma cells was obviously increased and the radioiodine therapy of carcinoma was effective after those genes had expressed in carcinoma cells. The main problem was that the effective half-time of radioiodine in cells was too short to produce the ideal effect of radioiodine therapy. Moreover, 211At and 188Re could be transferred by sodium/iodine symporter and they could be used to treat the carcinoma that is capable of radioiodine uptake.
